Description:
Alzheimer’s Disease (AD) is the most common form of dementia in adults 65 years and older. AD is associated with amyloid plaques containing amyloid-β peptides of 40 and 42 peptides (Aβ40 and Aβ42). Currently Aβ42, total Tau (tTau) and phosphorylated Tau 181 (pTau) are well-established biomarkers of AD, but they require invasive or expensive tests with limited availability. These investigators have developed a blood test that uses highly specific antibodies followed by mass spectrometry to measure the ratio of Aβ42/Aβ40 and compared these results with amyloid PET scans and cerebrospinal fluid pTau/Aβ42 measures in the same subjects. They present data indicating that the Aβ42/Aβ40 ratio, especially in combination with APOE ε4 genotype, accurately diagnoses brain amyloidosis and can be used to screen cognitively normal individuals for brain amyloidosis…
